118. Myelomeningocele Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 5 / Drugs : 7 - (DrugBank : 4) / Drug target genes : 2 - Drug target pathways : 10
Myelomeningocele and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability
ID | Diseases (Sorted by drug repositionability) |
---|---|
118 | Myelomeningocele |
6 | Parkinson disease |
169 | Menkes disease |
170 | Occipital horn syndrome |
22 | Moyamoya disease |
11 | Myasthenia gravis |
206 | Fragile X syndrome |
113 | Muscular dystrophy |
17 | Multiple system atrophy |
5 | Progressive supranuclear palsy |
70 | Spinal stenosis |
96 | Crohn disease |
2 | Amyotrophic lateral sclerosis |
46 | Malignant rheumatoid arthritis |
280 | Huge arteriovenous malformation with cervicofacial or limb lesion |
288 | Autoimmune acquired coagulation factor deficiency |
8 | Huntington disease |
13 | Multiple sclerosis/Neuromyelitis optica |
323 | Aromatic L-amino acid decarboxylase deficiency |
57 | Idiopathic dilated cardiomyopathy |
215 | Tetralogy of Fallot |
210 | Single Ventricle |
127 | Frontotemporal lobar degeneration |
226 | Interstitial cystitis with Hunners ulcer |
85 | Idiopathic interstitial pneumonia |
86 | Pulmonary arterial hypertension |
212 | Tricuspid atresia |
4 | Primary lateral sclerosis |
254 | Porphyria |
67 | Polycystic kidney disease |
78 | Hypopituitarism |
21 | Mitochondrial disease |
58 | Hypertrophic cardiomyopathy |
90 | Retinitis pigmentosa |
107 | Juvenile idiopathic arthritis |
28 | Systemic amyloidosis |
34 | Neurofibromatosis |
65 | Primary immunodeficiency |
111 | Congenital myopathy |